Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. [electronic resource] by
- Innes, A J
- Beattie, R
- Sergeant, R
- Damaj, G
- Foroni, L
- Marin, D
- Kanfer, E
- Mielke, S
- Milojkovic, D
- MacDonald, D
- Pavlu, J
- Rahemtulla, A
- Roberts, I
- Slade, D
- Bray, E
- Goldman, J
- Apperley, J
- Szydlo, R
- Dazzi, F
- Rezvani, K
Producer: 20140709
In:
Bone marrow transplantation vol. 48
Availability: No items available.
|